Skip to main content
CTEV $38.12 -9.71%
CTEV logo

CTEV · Claritev Corp

Track CTEV — free
$38.12 -4.10 (-9.71%) At close · Aug 14
Market Cap
$646.04M
Shares
16.95M
All earnings calls

Earnings call · FY2025 Q4

Claritev Corp Q4 FY2025 Earnings Call

Claritev Corp Q4 FY2025 Earnings Call

Concluded Feb 23, 2026
Feb 23, 2026 9 turns
Period
FY2025 Q4
Runtime
Sources
3 artifacts

Executive readout · one minute

What matters this quarter

Claritev reported Q4 2025 revenue of $246.6M (+6.2% YoY) and full-year revenue of $965.4M (+3.7%), returning to top-line growth, and initiated 2026 guidance of $980M–$1B revenue and $605M–$615M adjusted EBITDA alongside a new $75M share repurchase program.

Competitive Advantages 23 Adjusted EBITDA & Margins 21 AI Strategy 17 Profitable Growth / Turnaround 12 Cloud / OpEx Investment 8 Revenue Guidance 2026 8

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes
  • “we have returned to profitable growth sooner than expected”
  • “we are well positioned to meet these pressing needs with our network innovation, claims intelligence, transparency, and predictive employer tools”
  • “We have traditionally modeled for more conservative expectations for both volumes and inflation related growth, which is reflected in our initial guide.”

Forward guidance

5 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $246.55M +6.2% YoY
Net income · derived Q4 -$80.57M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q4 2025 revenue grew 6.2% year-over-year, continuing the return to growth
  • Full-year 2025 revenue increased 3.7% to $965.4M and adjusted EBITDA rose 4.5% to $602.6M
  • 2026 revenue guidance of $980M–$1B (4%–6% growth excluding $18M of one-time 2025 revenue) and adjusted EBITDA of $605M–$615M (61%–62% margins)
  • Board approved a $75M five-year share repurchase program (up to $20M per year)
  • Management highlighted record bookings and strong double-digit ACV bookings growth planned
  • 2026 expected to deliver double-digit operating and unlevered free cash flow growth with adjusted cash conversion normalizing to 50%–55%

Risks & pressure points

  • 2026 free cash flow guidance of only $0M–$10M, with $160M–$170M in capital expenditures and $10M–$15M of cloud-migration OpEx previously classified as CapEx
  • Q1 2026 expected to see low single-digit growth with a one-time revenue headwind
  • Full-year 2025 net loss of $284.3M and Q4 net loss of $80.6M
  • Management models conservatively on out-of-network claims volume (~7% of total) and medical inflation, which could pressure PSAV revenue assumptions

Key moments

Jump directly to management's words in the synchronized transcript.

“We are initiating 2026 revenue at $980 million to $1 billion, representing 2% to 4% growth over 2025. Excluding the $18 million of one-time revenue in 2025, we are modeling 4% to 6% growth this year.” Doug Garis, CFO
“We are forecasting total capital of $160 million to $170 million, and we are projecting free cash flow of $0 million to $10 million this year.” Doug Garis, CFO

Forward guidance

From the 8-K filed Feb 23, 2026.

Metric Guided
Revenues table
Full Year 2026
$980M – $1B
Adjusted EBITDA table
Full Year 2026
$605M – $615M
Capital expenditures table
Full Year 2026
$160M – $170M
Free cash flow table
Full Year 2026
$0 – $10M
Effective tax rate table
Full Year 2026
24% – 28%
Full-screen source Call document